DrugPatentWatch Database Preview
CINVANTI Drug Profile
When do Cinvanti patents expire, and when can generic versions of Cinvanti launch?
Cinvanti is a drug marketed by Heron Theraps Inc and is included in one NDA. There are five patents protecting this drug.
This drug has five patent family members in five countries.
The generic ingredient in CINVANTI is aprepitant. There are twenty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aprepitant profile page.
Summary for CINVANTI
| International Patents: | 5 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 71 |
| Patent Applications: | 74 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CINVANTI |
| DailyMed Link: | CINVANTI at DailyMed |
US Patents and Regulatory Information for CINVANTI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CINVANTI
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2017533183 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2016044784 | Start Trial |
| European Patent Office | 3193830 | Start Trial |
| South Korea | 20170056575 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for CINVANTI
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0734381 | PA2004002,C0734381 | Lithuania | Start Trial | PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111 |
| 0734381 | 04C0010 | France | Start Trial | PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111 |
| 0748320 | 08C0019 | France | Start Trial | PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111 |
| 0734381 | SPC/GB04/011 | United Kingdom | Start Trial | PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
